Product Description
Mechanisms of Action: CD56 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Lorvotuzumab mertansine](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Small Cell Lung Cancer|Leukemia|Pulmonary Blastoma|Synovial Sarcoma|Neuroblastoma|Wilms Tumor|Rhabdomyosarcoma|Neurofibrosarcoma
Phase 1: Carcinoma, Merkel Cell|Ovarian Cancer|Small Cell Lung Cancer|Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ADVL1522 | P2 |
Completed |
Synovial Sarcoma|Wilms Tumor|Pulmonary Blastoma|Neuroblastoma|Neurofibrosarcoma|Rhabdomyosarcoma |
2017-06-30 |
|
NCI-2015-00683 | P2 |
Completed |
Leukemia |
2017-06-06 |
|
2010-022950-17 | P2 |
Completed |
Small Cell Lung Cancer |
2015-05-12 |
|
Immunogen 0007 | P2 |
Terminated |
Small Cell Lung Cancer |
2015-05-01 |